DelveInsight’s, “Non Muscle Invasive Bladder Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including Non Muscle Invasive Bladder Cancer clinical trial and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Non Muscle Invasive Bladder Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Non Muscle Invasive Bladder Cancer clinical trial studies, Non Muscle Invasive Bladder Cancer NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Non-Muscle Invasive Bladder Cancer Pipeline Report
- DelveInsight’s Non Muscle Invasive Bladder Cancer Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Non Muscle Invasive Bladder Cancer.
- The leading Non Muscle Invasive Bladder Cancer Companies are working such as Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong Biomedical, Spectrum Pharmaceuticals, FKD therapies, Altor Biosciences, Heat Biologics, EMD Sereno, QED Therapeutics, and many others.
- Essential Non-Muscle Invasive Bladder Cancer pipeline therapies such as TL-532, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, Sasanlimab/PF-06801591, Nivolumab, APL-1202, UGN-102, Vesibax, and others are under development in different phases of clinical trials.
- The Non Muscle Invasive Bladder Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.
To explore more information on the latest breakthroughs in the Non Muscle Invasive Bladder Cancer Pipeline treatment landscape of the report, click here @ Non Muscle Invasive Bladder Cancer Pipeline Outlook
Non Muscle Invasive Bladder Cancer Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.
Latest Developmental Activities or News of the Non Muscle Invasive Bladder Cancer Treatment Landscape
- In November 2021, preliminary Phase II study (CORE1) results were presented for CG0070 in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). Results showed that a combination of CG0070 and pembrolizumab was well tolerated with encouraging early efficacy data in 9 patients.
- In October 2021, Asieris Pharmaceuticals initiated a Multi-center, Randomized, Open-label, Parallel-controlled Phase 3 Clinical Trial to Evaluate the Clinical Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk Non-muscle Invasive Bladder Cancer patients.
- UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Non-Muscle Invasive Bladder Cancer.
- Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells.
- In June 2021, LiPax, a precision-targeted, locally-delivered taxane being developed by Lipac oncology was found to induce a recurrence-free survival rate of 83% in patients with Non–Muscle Invasive bladder cancer who had undergone transurethral resection of bladder tumor.
For further information, refer to the detailed Non Muscle Invasive Bladder Cancer Unmet Needs, Non Muscle Invasive Bladder Cancer Market Drivers, and Non Muscle Invasive Bladder Cancer Market Barriers, click here for Non Muscle Invasive Bladder Cancer Ongoing Clinical Trial Analysis
Non Muscle Invasive Bladder Cancer Emerging Drugs Profile
- UGN-102: UroGen Pharma
UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Non Muscle Invasive Bladder Cancer.
- Sasanlimab: Pfizer
Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells. PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. Pfizer is developing PF-06801591 for the treatment of Non-muscle Invasive Bladder Cancer and is currently in phase III stage of development.
Non Muscle Invasive Bladder Cancer Therapeutic Assessment
There are approx. 30+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, UroGen Pharma.
Request a sample and discover the recent advances in Non-Muscle Invasive Bladder Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Non Muscle Invasive Bladder Cancer Treatment Landscape
Scope of the Non Muscle Invasive Bladder Cancer Pipeline Report
- Coverage- Global
- Non Muscle Invasive Bladder Cancer Companies- Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong Biomedical, Spectrum Pharmaceuticals, FKD therapies, Altor Biosciences, Heat Biologics, EMD Sereno, QED Therapeutics, and many others.
- Non Muscle Invasive Bladder Cancer Pipeline Therapies- TL-532, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, Sasanlimab/PF-06801591, Nivolumab, APL-1202, UGN-102, Vesibax, and others
- Non Muscle Invasive Bladder Cancer Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for drugs for Non Muscle Invasive Bladder Cancer Market Drivers and Non Muscle Invasive Bladder Cancer Market Barriers, click here @ Non Muscle Invasive Bladder Cancer Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Non Muscle Invasive Bladder Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Non Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- UGN-102: UroGen Pharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TLD 1433: Theralase Technologies
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- VAX-014: Vaxiion Therapeutics
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- Vesibax: Prokarium
- Drug profiles in the detailed report…..
- Inactive Products
- Non Muscle Invasive Bladder Cancer Key Companies
- Non Muscle Invasive Bladder Cancer Key Products
- Non Muscle Invasive Bladder Cancer- Unmet Needs
- Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
- Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
- Non Muscle Invasive Bladder Cancer Analyst Views
- Appendix
Got Queries? Find out the related information on Non-Muscle Invasive Bladder Cancer Mergers and acquisitions, Non Muscle Invasive Bladder Cancer Licensing Activities @ Non-Muscle Invasive Bladder Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services